PureTech Health (PRTC)
(Delayed Data from NSDQ)
$29.50 USD
+0.82 (2.86%)
Updated May 21, 2024 11:11 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
PRTC 29.50 +0.82(2.86%)
Will PRTC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for PRTC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PRTC
PureTech Health (PRTC) is on the Move, Here's Why the Trend Could be Sustainable
Down -8.13% in 4 Weeks, Here's Why PureTech Health PLC Sponsored ADR (PRTC) Looks Ripe for a Turnaround
PRTC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PRTC
PureTech-founded Vedanta begins trials for VE303 colonic bacteria drug
PureTech Entity Begins Landmark C. difficile Trial
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
PureTech-founded,Vedanta, enrollls 1st patient in RESTORATiVE303 sudy of VE303
IN BRIEF: PureTech Health launches USD100 million buyback programme